Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin together with ABI-007 works in treating patients with stage IV melanoma that cannot be removed by surgery.
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Genetic: protein expression analysis
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma|
- Tumor response as measured by RECIST criteria [ Designated as safety issue: No ]
- Toxicity profile [ Designated as safety issue: Yes ]
- Survival time [ Designated as safety issue: No ]
- Time to disease progression [ Designated as safety issue: No ]
- Duration of response [ Designated as safety issue: No ]
- Time to treatment failure [ Designated as safety issue: No ]
|Study Start Date:||October 2006|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
- Assess the safety and antitumor activity of carboplatin and paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) in patients with unresectable stage IV melanoma who have not received prior chemotherapy for their metastatic disease. (Cohort 1)
- Assess the safety and antitumor activity of this regimen in patients with unresectable stage IV melanoma who have received prior chemotherapy for their metastatic disease. (Cohort 2)
- Describe the impact of this regimen on parameters of immune function and angiogenesis in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to prior chemotherapy for metastatic disease (yes vs no).
Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.
After completion of study treatment, patients are followed periodically for up to 2 years.
PROJECTED ACCRUAL: A total of 74 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00404235
Show 156 Study Locations
|Study Chair:||Svetomir Markovic, MD, PhD||Mayo Clinic|
|Investigator:||Lisa Kottschade, RN, MSN, CNP||Mayo Clinic|
|Investigator:||Thomas T. Amatruda, MD||Humphrey Cancer Center - Fridley|
|Investigator:||Ravi D. Rao, MD, MBBS||Mayo Clinic|
|Investigator:||Judith S. Kaur, MD||Mayo Clinic|
|Investigator:||Henry C. Pitot, MD||Mayo Clinic|
|Investigator:||Gary A. Croghan, MD, PhD||Mayo Clinic|
|Investigator:||Robert McWilliams, MD||Mayo Clinic|
|Investigator:||Edward T. Creagan, MD||Mayo Clinic|